Impact of Hormonal Therapy on Endometriosis-Associated Pain and Fertility

Munazza Yousaf, Zareena Begum, Alden Er, Fatima Usama, Shermeen Kousar, Numan Ghani
In: Pakistan Journal of Medical & Health Sciences · 2023 · vol. 17(12) , pp. 147–150 · doi:10.53350/pjmhs020231712147 · W4411458403
OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-14 ⓘ

This prospective cohort study of 98 women with endometriosis found that GnRH agonists provided superior pain reduction and higher fertility rates compared to combined oral contraceptives or progestins, though adherence was lower.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-12 · read from full text ⓘ

This prospective cohort study evaluated the efficacy of progestins, combined oral contraceptives, and GnRH agonists in managing pain and fertility among 98 women with endometriosis. The results indicated that GnRH agonists provided the most significant pain reduction compared to other treatments, although they were associated with higher side effects and lower patient adherence. While ovulation and pregnancy rates were numerically highest in the GnRH group, these improvements did not reach statistical significance within the one-year observation period. This paper is centrally about endometriosis — specifically evaluating hormonal therapies for pain management and fertility outcomes in patients with the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Introduction: Endometriosis is a chronic gynecological condition associated with severe pelvic pain and infertility. Hormonal therapy, including GnRH agonists, combined oral contraceptives (COCs), and progestins, is widely used for symptom management. However, the comparative efficacy of these treatments in pain reduction and fertility outcomes remains unclear. This study aimed to evaluate the impact of hormonal therapy on endometriosis-associated pain and fertility. Methodology: This prospective cohort research was carried out from February 2023 to July 2023, at the department of Gynaecology and Obstetrics, Saidu Group of Teaching Hospitals, Swat and MMC General Hospital, Peshawar. Three treatment groups were created from 98 women with endometriosis diagnoses: progestins (n=33), COCs (n=32), and GnRH agonists (n=33). The Visual Analog Scale (VAS) was used to measure pain severity both at baseline and one year later. Ovulation and pregnancy rates were among the fertility outcomes that were documented. ANOVA, chi-square tests, and paired t-tests were used in the statistical analysis; a p-value of less than 0.05 was deemed statistically significant. Results: GnRH agonists showed the greatest pain reduction (VAS: 8.0 → 1.9, p < 0.001) but had the highest side effects and lowest adherence (69.7%). COCs and progestins demonstrated moderate pain relief with better tolerability (VAS reduction: 7.9 → 3.2 and 7.8 → 2.9, respectively). Ovulation and pregnancy rates were highest in the GnRH group (69.2% and 53.8%) but were not statistically significant (p > 0.05). Conclusion: Hormonal therapy effectively reduces endometriosis-associated pain, with GnRH agonists providing the best relief but lower adherence. Fertility outcomes showed improvement but lacked statistical significance. Further research is needed to assess long-term effects and optimize treatment strategies. Keywords: Endometriosis, Hormonal Therapy, GnRH Agonists, Pain Management, Fertility, Combined Oral Contraceptives, Progestins
Full text 2,379 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Introduction

Endometriosis is a chronic gynecological condition associated with severe pelvic pain and infertility. Hormonal therapy, including GnRH agonists, combined oral contraceptives (COCs), and progestins, is widely used for symptom management. However, the comparative efficacy of these treatments in pain reduction and fertility outcomes remains unclear. This study aimed to evaluate the impact of hormonal therapy on endometriosis-associated pain and fertility. Methodology: This prospective cohort research was carried out from February 2023 to July 2023, at the department of Gynaecology and Obstetrics, Saidu Group of Teaching Hospitals, Swat and MMC General Hospital, Peshawar. Three treatment groups were created from 98 women with endometriosis diagnoses: progestins (n=33), COCs (n=32), and GnRH agonists (n=33). The Visual Analog Scale (VAS) was used to measure pain severity both at baseline and one year later. Ovulation and pregnancy rates were among the fertility outcomes that were documented. ANOVA, chi-square tests, and paired t-tests were used in the statistical analysis; a p-value of less than 0.05 was deemed statistically significant.

Results

GnRH agonists showed the greatest pain reduction (VAS: 8.0 → 1.9, p < 0.001) but had the highest side effects and lowest adherence (69.7%). COCs and progestins demonstrated moderate pain relief with better tolerability (VAS reduction: 7.9 → 3.2 and 7.8 → 2.9, respectively). Ovulation and pregnancy rates were highest in the GnRH group (69.2% and 53.8%) but were not statistically significant (p > 0.05).

Conclusion

Hormonal therapy effectively reduces endometriosis-associated pain, with GnRH agonists providing the best relief but lower adherence. Fertility outcomes showed improvement but lacked statistical significance. Further research is needed to assess long-term effects and optimize treatment strategies.

Keywords

Endometriosis, Hormonal Therapy, GnRH Agonists, Pain Management, Fertility, Combined Oral Contraceptives, Progestins Downloads How to Cite Issue Section License Copyright (c) 2023 Munazza Yousaf, Zareena Begum, Abeer, Fatima Usama, Shermeen Kousar, Naureen Ghani This work is licensed under a Creative Commons Attribution 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

VAS-pain

Condition tags

endometriosisinfertility

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK